In this phase I , randomized , observer-blind , dose-ranging study , @ healthy subjects @ years of age were randomized to receive @ vaccinations with H@N@c cell-culture-derived vaccine doses containing @ g , @ g , or @ g hemagglutinin antigen of H@N@v with or without MF@ ( registered trademark of Novartis AG ) adjuvant ( an oil-in-water emulsion ) .